Opening question: When a research-peptide listing flashes an “FDA peptide,” THPdb screenshot, or approved-therapeutic-peptide badge, how do you tell curated FDA-approved peptide/protein database literacy apart from proof the catalog vial is that approved drug?
Short answer: open the live THPdb2 database (Raghava Lab, IIIT-Delhi) and its methods paper, Jain, Gupta, Patiyal & Raghava, Drug Discovery Today (2024) (DOI 10.1016/j.drudis.2024.104047; PMID 38830503). THPdb2 compiles detailed records for approved and approved/investigational therapeutic peptides and proteins—description, sequence, indication, mechanism, pharmacokinetics fields, targets, and related attributes drawn from public regulatory/drug sources. That is literacy about which peptides already sit in the approved-therapeutic catalog. It is not evidence that a research-only SKU with a similar name or motif is that product—or that you may use a research chemical as medicine.
A practical THPdb2 checklist when listings lean on “FDA peptide” screenshots:
- Database entry ≠ your bottle: A THPdb2 hit identifies an approved or investigational therapeutic peptide/protein record. It does not authenticate an unlabeled research vial, prove matching identity/purity, or authorize human use of a research catalog item.
- Approved/investigational labels are specific: THPdb2 distinguishes curated therapeutic entries with indication and pharmacology fields. Ads that paste an FDA logo next to a research peptide without a matching approved identity are borrowing regulatory prestige.
- Distinct from prediction and ACP catalogs: CancerPPD curates experimentally reported anticancer peptide literature; AntiCP scores sequences in silico; THPdb2 tracks therapeutic peptides/proteins with regulatory status context. Do not treat any one badge as interchangeable clearance.
- What to open next: If a listing implies a research peptide is “the same as an FDA-approved peptide in THPdb2,” open THPdb2 and Jain et al. and compare sequence, name, and status fields—then ask whether the claim teaches regulatory-catalog literacy or dresses a research chemical with approval language.
None of those steps turns a laboratory research listing into an approved medicine. Company research-only catalogs document laboratory intent and paperwork such as certificates of analysis; they do not create human-use approval. For company facts only—not clinical evidence—Apollo Peptides states products are for laboratory research only, not for human or veterinary use, and describes third-party testing with certificates of analysis.
Bottom line: Use THPdb2 to read approved/investigational therapeutic peptide records honestly—what status and pharmacology fields actually say, how that differs from a research listing, and what an “FDA peptide” badge does not prove about a vial—then notice whether the listing is teaching catalog literacy or borrowing approval language. That habit changes what you verify before trusting a regulatory-looking badge—it is not advice to buy, inject, or dose any peptide.
By The Everyday Brief · AI-assisted editorial. Drafted with AI research assistance; claims checked against the THPdb2 database home and Jain et al. Drug Discovery Today 2024 (DOI 10.1016/j.drudis.2024.104047; PMID 38830503) via EuropePMC (fetched 2026-10-04 PT). No invented studies, quotes, or dosing. Not medical or legal advice.
Sources
1. THPdb2 — database of FDA-approved therapeutic peptides and proteins (Raghava Lab)
2. Jain et al., Drug Discovery Today 2024 (DOI 10.1016/j.drudis.2024.104047)
3. PMID 38830503 — PubMed record for THPdb2
4. EuropePMC record for THPdb2 (PMID 38830503)
5. Apollo Peptides (company facts only)
Related reading
AntiCP 2.0 scores are not research-peptide cancer clearance
BIOPEP-UWM literacy when peptide ads flash bioactive-peptide database screenshots
CellPPD CPP scores are not research-peptide delivery approval